CASE REPORT: Fulminant acute hemorrhagic Leukoencephalitis (AHLE): A rare and ruinous outcome with cerebral herniation (COVID-19).

Acute Disease Hemorrhagic Hurst Leukoencephalitis

Journal

eNeurologicalSci
ISSN: 2405-6502
Titre abrégé: eNeurologicalSci
Pays: Netherlands
ID NLM: 101667077

Informations de publication

Date de publication:
Jun 2024
Historique:
received: 17 01 2024
revised: 31 03 2024
accepted: 04 04 2024
medline: 17 4 2024
pubmed: 17 4 2024
entrez: 17 4 2024
Statut: epublish

Résumé

Acute hemorrhagic leukoencephalitis (AHLE) is a very rare demyelinating disease with rapid fulminant inflammation of the white matter. Although the exact etiology is unknown, AHLE usually manifests post a viral or bacterial infection and less often seen post vaccination for measles or rabies. AHLE has a very poor prognosis and a high mortality rate. Owing to the rarity of this entity there is not clear consensus on the proper line of management. In this report, we present a case of AHLE as a para-infectious sequel to COVID-19 in a young patient. We report a 30-year-old turkish patient with an initial presentation of upper respiratory tract infection due to COVID-19. Initially, she was admitted to the hospital with generalized tonic-clonic seizure (GTCS) and deterioration in her level of consciousness lapsing into a coma. An initial CT scan showed diffuse brain edema and an MRI head confirmed the suspicion of Acute hemorrhagic leukoencephalitis (AHLE). Despite prompt and diligent osmotic therapy and pulsed intravenous (IV) methylprednisolone, her condition rapidly depreciated and progressed into cerebral edema with gravid sequela of brainstem herniation. AHLE is a very rare entity and perhaps its fulminant debilitating course and high mortality should warrant further studies on disease pathophysiology and its optimal treatment parameters. Life-saving decompressive hemicraniectomy should be considered in the multidisciplinary approach of the management with tailored osmotic and immunotherapy.

Sections du résumé

Background UNASSIGNED
Acute hemorrhagic leukoencephalitis (AHLE) is a very rare demyelinating disease with rapid fulminant inflammation of the white matter. Although the exact etiology is unknown, AHLE usually manifests post a viral or bacterial infection and less often seen post vaccination for measles or rabies. AHLE has a very poor prognosis and a high mortality rate. Owing to the rarity of this entity there is not clear consensus on the proper line of management. In this report, we present a case of AHLE as a para-infectious sequel to COVID-19 in a young patient.
Clinical presentation UNASSIGNED
We report a 30-year-old turkish patient with an initial presentation of upper respiratory tract infection due to COVID-19. Initially, she was admitted to the hospital with generalized tonic-clonic seizure (GTCS) and deterioration in her level of consciousness lapsing into a coma. An initial CT scan showed diffuse brain edema and an MRI head confirmed the suspicion of Acute hemorrhagic leukoencephalitis (AHLE). Despite prompt and diligent osmotic therapy and pulsed intravenous (IV) methylprednisolone, her condition rapidly depreciated and progressed into cerebral edema with gravid sequela of brainstem herniation.
Conclusions UNASSIGNED
AHLE is a very rare entity and perhaps its fulminant debilitating course and high mortality should warrant further studies on disease pathophysiology and its optimal treatment parameters. Life-saving decompressive hemicraniectomy should be considered in the multidisciplinary approach of the management with tailored osmotic and immunotherapy.

Identifiants

pubmed: 38628435
doi: 10.1016/j.ensci.2024.100499
pii: S2405-6502(24)00006-6
pmc: PMC11019095
doi:

Types de publication

Case Reports

Langues

eng

Pagination

100499

Informations de copyright

© 2024 The Authors. Published by Elsevier B.V.

Déclaration de conflit d'intérêts

The authors have no conflicts of interest to disclose.

Auteurs

Abeer Sabry Safan (AS)

Department of Neurology, Neurosciences Institute, Hamad Medical Corporation, Doha, Qatar.

Zeba Noorain (Z)

Department of Neurology, Neurosciences Institute, Hamad Medical Corporation, Doha, Qatar.

Mohamed A Atta (MA)

Department of Internal Medicine, Hamad Medical Corporation, Doha, Qatar.

Razna Thekkoth (R)

Department of Emergency, Hamad Medical Corporation, Doha, Qatar.

Aasir M Suliman (AM)

Department of Internal Medicine, Hamad Medical Corporation, Doha, Qatar.

Abdalrazig Fadlelmula (A)

Department of Medical intensive Critical care, Hamad Medical Corporation, Doha, Qatar.

Mohammed Abdelatey (M)

Department of Medical intensive Critical care, Hamad Medical Corporation, Doha, Qatar.

Classifications MeSH